Continuous glucose monitoring metrics following sub-Tenon's injection of triamcinolone acetonide for diabetic macular edema.
Graefes Arch Clin Exp Ophthalmol
; 262(2): 449-456, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-37864636
ABSTRACT
PURPOSE:
This pilot study aims to comprehensively evaluate the effects of sub-Tenon's injection of triamcinolone acetonide (STTA) on glycemic control in patients with diabetic macular edema (DME) using professional continuous glucose monitoring (CGM).METHODS:
This retrospective study analyzed changes in glycemic control in 20 patients with type 2 mellitus and DME following single STTA (20 mg/0.5 mL) using The FreeStyle Libre Pro system. Professional CGM provides core CGM metrics such as the percentage of time that glucose levels fall within a target range and include the time in range (TIR) (70-180 mg/dL), time above range (TAR) (> 180 mg/dL), and time below range (TBR) (< 70 mg/dL). Outcome measures were the changes in CGM metrics (TIR, TAR and TBR) and the percentage of patients in whom TAR increased by at least 10 percentage points (ppt) 4 days before to 4 days after STTA administration.RESULTS:
The mean CGM metrics (TIR/TAR/TBR) were 75.5%/19.9%/4.4% 4 days before STTA and 73.7%/22.4%/3.5% 4 days after STTA; the metrics 4 days before and 4 days after STTA were not significantly different (P = 0.625 for TIR, P = 0.250 for TAR, and P = 0.375 for TBR). TAR increased by more than 10 ppt in four (20%) patients treated with sulfonylurea and/or insulin.CONCLUSION:
Although there were no significant changes in the CGM metrics, four patients developed CGM-measured hyperglycemia after STTA for DME.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Edema Macular
/
Diabetes Mellitus Tipo 1
/
Retinopatia Diabética
Limite:
Humans
Idioma:
En
Revista:
Graefes Arch Clin Exp Ophthalmol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Japão